| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | BRD-K45681478 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | A-804598 | CTRPv2 | pan-cancer | AAC | 0.05 | 0.3 |
| mRNA | CID-5951923 | CTRPv2 | pan-cancer | AAC | 0.041 | 0.3 |
| mRNA | Obatoclax Mesylate | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.056 | 0.3 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.3 |
| mRNA | foretinib | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |